Considering the late-stage expression profile of GNAi2/gip2 in ovarian cancer, the hub and bottleneck nodes identified here, especially the metabolic signaling nodes such as UQCRFS1, should provide newer targets for the development of second-line targeted therapy for advanced ovarian cancers. This evidence concerns the gene GNAI2 and ovarian carcinoma.